Itacitinib: all 47 studies that test it
Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.
- Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell TherapyRecruitingNCT05757219Phase 2
- Safety and Efficacy of Itacitinib in Adults With Systemic SclerosisRecruitingNCT04789850Phase 2
- Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)RecruitingNCT04061421Phase 1/2
- To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)CompletedNCT04629508Phase 2Results posted
- Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHDTerminatedNCT04446182Phase 2Results posted
- Itacitinib in Advanced Hepatocellular CarcinomaCompletedNCT04358185Phase 1Results posted
- A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)TerminatedNCT04200365Phase 2Results posted
- Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung TransplantationTerminatedNCT03978637Phase 1/2Results posted
- Itacitinib for Low Risk GVHDCompletedNCT03846479Phase 2Results posted
- Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell TransplantationCompletedNCT03755414Phase 1Results posted
- Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric SubjectsTerminatedNCT03721965Phase 1/2Results posted
- Itacitinib + Everolimus in Hodgkin LymphomaActive, not recruitingNCT03697408Phase 1/2Results posted
- GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host DiseaseTerminatedNCT03584516Phase 2/3Results posted
- Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung CancerTerminatedNCT03425006Phase 2Results posted
- INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.TerminatedNCT03272464Phase 1Results posted
- GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host DiseaseCompletedNCT03139604Phase 3Results posted
- A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT02760485Phase 1/2Results posted
- A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)CompletedNCT02018861Phase 1/2Results posted
- Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older PatientsActive, not recruitingNCT05823571Phase 1
- Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint InhibitorsWithdrawnNCT05660421Phase 2
- Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell TransplantsActive, not recruitingNCT05364762Phase 2
- Treatment of Non Severe Hemophagocytosis Lymphohistiocytosis With ITACITINIBCompletedNCT05063110Phase 2
- Itacitinib for the Prevention of Graft Versus Host DiseaseActive, not recruitingNCT04859946Phase 2
- A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of ItacitinibTerminatedNCT04640025Phase 2
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingNCT04591431Phase 2
- Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)Active, not recruitingNCT04509700Phase 2
- Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell TransplantTerminatedNCT04239989Phase 1
- A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host DiseaseTerminatedNCT04220632Phase 1/2
- Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell TransplantationWithdrawnNCT04127721Phase 2
- Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host DiseaseTerminatedNCT04070781Phase 1
- Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic LeukemiaCompletedNCT03989466Phase 1
- Itacitinib in Treating Patients With Refractory Metastatic/Advanced SarcomasTerminatedNCT03670069Phase 1
- A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative ColitisWithdrawnNCT03627052Phase 2
- Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese SubjectsCompletedNCT03497273Phase 1
- GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host DiseaseTerminatedNCT03320642Phase 1
- An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung CancerCompletedNCT02917993Phase 1/2
- Relieving Chronic Itch: Oral MedicationWithdrawnNCT02909569Phase 2
- Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid TumorsCompletedNCT02646748Phase 1
- Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHDCompletedNCT02614612Phase 1
- INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin LymphomaTerminatedNCT02456675Phase 2
- Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating MutationsWithdrawnNCT02355431Phase 2
- Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung CancerTerminatedNCT02257619Phase 2
- Study of INCB040093 in Subjects With Previously Treated B-Cell MalignanciesCompletedNCT01905813Phase 1
- Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid TumorsCompletedNCT01858883Phase 1/2
- A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque PsoriasisCompletedNCT01634087Phase 2
- An Open Label Study of Itacitinib Administered Orally in Patients With MyelofibrosisCompletedNCT01633372Phase 2
- A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid ArthritisCompletedNCT01626573Phase 2